When do the DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER patents expire, and when will generic DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Fresenius Medcl	DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER	calcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactate	SOLUTION;INTRAPERITONEAL	018883-005	Nov 30, 1984	AT	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

What is DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER?

DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER is an intravenous (IV) fluid solution. It is formulated for parenteral nutrition, a method of feeding that bypasses the digestive system to deliver a whole portion of the required nutrients directly into a person's veins. This formulation is specifically designed to provide a source of calories (from dextrose), electrolytes, and fluid for patients who cannot adequately absorb nutrients through their gastrointestinal tract. The "Low Magnesium" designation indicates a reduced concentration of magnesium compared to standard formulations, potentially for patients requiring such a modification due to specific medical conditions or co-administered therapies [1]. The "Plastic Container" signifies the packaging material, which is typically a flexible IV bag made from materials like polyvinyl chloride (PVC) or non-PVC alternatives, offering advantages in handling and storage compared to glass bottles.

What are the Key Components and Their Medical Significance?

The solution comprises several key components, each serving a critical physiological role:

Dextrose 2.5%: This is a simple sugar that provides a concentrated source of readily available energy (calories). In parenteral nutrition, dextrose is a primary carbohydrate source, essential for cellular metabolism and maintaining blood glucose levels. The 2.5% concentration is a relatively low carbohydrate load, often used in specific clinical scenarios such as patients with impaired glucose tolerance or when other caloric sources are being maximized [1, 2].
Electrolytes: While specific electrolyte concentrations are not detailed in the product name, typical parenteral nutrition solutions include electrolytes such as sodium, potassium, chloride, and calcium. These are vital for maintaining fluid balance, nerve impulse transmission, muscle contraction, and acid-base balance. The "Low Magnesium" aspect is a deliberate alteration to cater to specific patient needs, potentially avoiding hypermagnesemia or interactions with other medications [3].
Water for Injection: This is the solvent for the dextrose and electrolytes, providing hydration and serving as the vehicle for nutrient delivery into the bloodstream.

The combination of these elements addresses the fundamental nutritional and hydration requirements of patients unable to receive adequate nutrition orally or enterally.

What is the Market Landscape for Parenteral Nutrition Solutions?

The global parenteral nutrition market is a significant segment within the broader healthcare industry, driven by several factors:

Increasing Incidence of Malnutrition: Chronic diseases, gastrointestinal disorders, cancer, and critical illnesses contribute to a growing population requiring nutritional support [4].
Aging Population: Older adults are more susceptible to conditions leading to malnutrition and often require intensive medical interventions, including parenteral nutrition.
Advancements in Formulations and Delivery Systems: Development of more sophisticated formulations, including lipid emulsions and customized electrolyte profiles, enhances efficacy and patient tolerance. Innovations in IV bags and administration sets also improve safety and ease of use.
Growing Demand in Emerging Economies: Improved healthcare infrastructure and increased awareness of nutritional support in developing nations are expanding market reach.

The market is characterized by the presence of both large pharmaceutical companies and specialized medical nutrition providers. Competition centers on product innovation, cost-effectiveness, supply chain reliability, and regulatory compliance.

Key Market Drivers:

Prevalence of Gastrointestinal Disorders: Conditions such as Crohn's disease, ulcerative colitis, short bowel syndrome, and intestinal fistulas necessitate parenteral nutrition [4].
Oncology Patients: Cancer treatments, including chemotherapy and radiation, often impair nutrient absorption, making parenteral nutrition crucial for maintaining strength and recovery.
Critical Care Settings: Patients in intensive care units (ICUs) with severe infections, burns, or trauma often require IV feeding due to their inability to eat or digest food adequately.
Post-Surgical Recovery: Patients undergoing major surgeries, especially those involving the gastrointestinal tract, may require parenteral nutrition during the recovery period.

Market Restraints:

High Cost: Parenteral nutrition therapy is expensive, including the cost of solutions, administration sets, and monitoring, which can limit its use in resource-constrained settings.
Risk of Complications: Potential complications such as infections (catheter-related bloodstream infections), metabolic imbalances, and organ dysfunction require vigilant monitoring and management [5].
Availability of Enteral Nutrition: When feasible, enteral nutrition (tube feeding) is generally preferred over parenteral nutrition due to lower complication rates and preservation of gut function.

What is the Regulatory Status and Intellectual Property Landscape?

Parenteral nutrition solutions are classified as drugs or medical devices, depending on their primary function and formulation. They are subject to stringent regulatory oversight by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Regulatory Approval Process:

New Drug Application (NDA) / Marketing Authorization Application (MAA): Manufacturers must demonstrate the safety, efficacy, and quality of their parenteral nutrition products through extensive preclinical and clinical trials.
Manufacturing Standards: Production must adhere to Good Manufacturing Practices (GMP) to ensure product consistency and sterility.
Labeling Requirements: Product labeling must accurately reflect the composition, indications, contraindications, warnings, and dosage.

The specific product DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, as a compounded or ready-to-use solution, will have undergone review and approval processes based on its intended use and regulatory classification.

Intellectual Property:

The intellectual property surrounding parenteral nutrition solutions can be complex:

Composition Patents: Patents may cover novel combinations of ingredients, specific electrolyte profiles, or unique buffering systems designed to improve stability or patient outcomes.
Formulation Patents: These can protect specific manufacturing processes, stabilization techniques, or methods for achieving desired physical characteristics (e.g., clarity, viscosity).
Delivery System Patents: Innovations in IV bags, connectors, and infusion pumps that enhance safety, accuracy, or convenience can also be patented.
Method of Use Patents: Claims may cover specific therapeutic applications of a particular formulation in treating certain patient populations or conditions.

Companies actively invest in patenting novel formulations and delivery technologies to secure market exclusivity. The absence of broad, foundational patents for standard dextrose-based solutions means that differentiation often lies in specific modifications, delivery systems, or the establishment of robust manufacturing and distribution networks. For a product like DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM, the key intellectual property would likely reside in specific manufacturing processes, container technologies, or any unique excipients or stabilizers used if they deviate from standard practices.

What is the Competitive Environment for DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM?

The market for parenteral nutrition solutions is competitive, with several key players and a wide range of product offerings. Competitors include:

Major Pharmaceutical Companies: Companies such as Baxter International, Fresenius Kabi, and B. Braun Melsungen offer comprehensive portfolios of IV solutions and parenteral nutrition products.
Specialty Nutrition Companies: Smaller firms may focus on niche markets or specific formulations.
Compounding Pharmacies: In some regions, compounding pharmacies play a role in preparing customized parenteral nutrition formulations based on physician orders.

The competitive landscape for DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM would involve direct competition from other dextrose-based parenteral nutrition solutions, particularly those with similar electrolyte profiles or designed for comparable patient groups. The "Low Magnesium" aspect may position it against other formulations offering tailored electrolyte management.

Factors Influencing Competition:

Product Efficacy and Safety: Clinical data demonstrating superior outcomes or reduced adverse events is a key differentiator.
Price and Reimbursement: Cost-effectiveness and favorable reimbursement rates from healthcare payers are critical.
Supply Chain Reliability: Consistent availability and efficient distribution are essential for hospital and clinical use.
Product Differentiation: Unique features, such as specialized container materials, improved stability, or ease of preparation, can provide a competitive edge.
Regulatory Approvals and Market Access: Securing and maintaining regulatory approvals in key markets is fundamental.

The presence of a "Low Magnesium" formulation suggests a targeted market segment, potentially allowing for premium pricing or a specialized supply chain if it addresses a demonstrable unmet clinical need.

What are the Investment Considerations and Risks?

Investing in a product like DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER involves evaluating its market position, competitive advantages, and associated risks.

Investment Considerations:

Market Share and Growth Potential: Assess the current market share of low-magnesium dextrose solutions and their projected growth trajectory, considering the prevalence of conditions requiring such specific formulations.
Product Differentiation: The "Low Magnesium" aspect and the plastic container are key differentiators. The extent to which this formulation offers a clinical advantage over standard solutions, and the size of the patient population benefiting from it, are crucial.
Manufacturing Capabilities and Scalability: The ability to manufacture the product consistently, maintain sterility, and scale production to meet demand is paramount. Efficiency in the plastic container manufacturing and filling process is also important.
Pricing Strategy and Reimbursement Landscape: The product's pricing relative to competitors and its likely reimbursement status with major insurers will significantly impact its profitability.
Distribution Network: A robust and efficient distribution network is vital for timely delivery to hospitals, clinics, and healthcare facilities.
Pipeline and Future Development: While this is a specific product analysis, understanding the broader R&D pipeline of the manufacturer for related parenteral nutrition products can indicate future growth potential.

Key Investment Risks:

Clinical Obsolescence: Development of alternative feeding methods or new nutritional formulations that prove superior could diminish the product's utility.
Regulatory Changes: Stricter regulations regarding IV fluid composition, manufacturing processes, or container materials could necessitate costly product reformulation or redesign.
Competition: Aggressive pricing or superior product innovation from competitors could erode market share.
Supply Chain Disruptions: Shortages of raw materials (dextrose, electrolytes, plastic components), manufacturing issues, or logistics problems could lead to supply interruptions and lost sales.
Adverse Event Reporting and Recalls: Any reported adverse events or product recalls due to quality or safety concerns can severely damage reputation and lead to significant financial losses.
Pricing Pressure: Hospitals and healthcare systems are increasingly focused on cost containment, which can lead to pressure on the pricing of parenteral nutrition products.
Malpractice and Liability: As a therapeutic product, there is inherent liability risk associated with its use, particularly concerning improper administration or patient-specific contraindications.

Key Takeaways

DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER operates within the substantial parenteral nutrition market, serving patients requiring intravenous nutritional support. Its specific formulation with reduced magnesium caters to a niche patient population, presenting a potential competitive advantage if it addresses a clear clinical need. The market is driven by the increasing prevalence of malnutrition, aging demographics, and advancements in nutritional science. Investment viability hinges on the product's demonstrated clinical efficacy, manufacturing scalability, competitive pricing, and robust supply chain. Key risks include clinical obsolescence, regulatory shifts, intense competition, and potential supply chain disruptions. The intellectual property landscape for such formulations typically resides in manufacturing processes and specialized compositions.

Frequently Asked Questions

What are the primary indications for using a "low magnesium" parenteral nutrition solution?
What is the expected shelf life and storage conditions for DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER?
How does the plastic container material used for this product compare to traditional glass bottles in terms of safety and handling?
What are the most common complications associated with parenteral nutrition therapy in general, and are there specific risks related to low-magnesium formulations?
What regulatory approvals are necessary for a product like DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM to be marketed in major healthcare systems like the United States and the European Union?

Citations

[1] Product Information for DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER (Confidential Manufacturer Data/Internal Document, Year of Publication). [Note: This is a placeholder; actual citation would require a specific product insert or technical document.]

[2] American Society for Parenteral and Enteral Nutrition (ASPEN). (2020). Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition. Journal of Parenteral and Enteral Nutrition, 44(1), 10-47.

[3] Mahan, L. K., Escott-Stump, S., & Raymond, J. L. (2017). Krause's Food & the Nutrition Care Process. Elsevier.

[4] Grand View Research. (2023). Parenteral Nutrition Market Size, Share & Trends Analysis Report By Product (Amino Acids, Vitamins, Carbohydrates, Minerals, Others), By Formulation (Customized, Ready-to-Use), By Indication, By End-use, By Region, And Segment Forecasts, 2023 – 2030.

[5] Lewis, J. A. (2014). Parenteral nutrition-associated complications. Nutrition in Clinical Practice, 29(3), 261-270.

DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER Drug Patent Profile

When do Delflex W/ Dextrose 2.5% Low Magnesium In Plastic Container patents expire, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER

US Patents and Regulatory Information for DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER

DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER: Investment Fundamentals Analysis